IMM Immupharma Plc

RNS: RELEASE                                                                                                                                                   5 June 2024

ImmuPharma PLC

("ImmuPharma" or the "Company")

Notice of AGM & Annual Report & Accounts

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to confirm that the Company's Annual General Meeting ("AGM") will be held on Friday 28 June 2024 @ 11:00a.m. (BST), at the offices of Evelyn Partners, 45 Gresham Street, London, EC2V 7BG.

The Notice of AGM setting out details of the resolutions, together with the Company's Annual Report and Accounts for the year ended 31 December 2023, has been posted to those shareholders requesting a postal copy; and for other shareholders, these documents will shortly be available to view and download on the Company's website: www.immupharma.co.uk.

Ends

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 is a first-in class autophagy immunomodulator for the treatment of Lupus and CIDP and preclinical analysis suggests P140 may have therapeutic benefit in many other autoimmune diseases that are caused by the same dysfunction in the immune system.

For additional information about ImmuPharma please visit: www.immupharma.co.uk

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.